Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from Galapagos ( (GLPG) ) is now available.
On March 17, 2026, Galapagos NV reported that it had received a transparency notification from Bank of America Corporation under Belgian disclosure rules, following a reduction in Bank of America’s economic exposure to the company. The notification showed that, as of March 10, 2026, Bank of America and its affiliates had fallen below the 5% threshold of Galapagos’ voting rights, holding a combined 3.91% through 421,092 shares and 2,158,293 equivalent financial instruments out of 65,897,071 outstanding shares.
The move reflects a shift in a major financial institution’s position in Galapagos but leaves Bank of America with a non-negligible, though no longer notifiable, stake in the biotech group. While the filing does not alter Galapagos’ operational outlook, it provides investors with increased visibility on the company’s evolving shareholder base and the level of institutional interest in its equity.
The most recent analyst rating on (GLPG) stock is a Sell with a $22.00 price target. To see the full list of analyst forecasts on Galapagos stock, see the GLPG Stock Forecast page.
Spark’s Take on GLPG Stock
According to Spark, TipRanks’ AI Analyst, GLPG is a Neutral.
GLPG scores strongest on financial positioning (very low leverage and large cash resources) and supported valuation (low P/E). The main offset is persistent negative operating/free cash flow and earnings quality concerns highlighted by non-recurring profit drivers and ongoing restructuring/wind-down cash needs; technical signals are broadly neutral.
To see Spark’s full report on GLPG stock, click here.
More about Galapagos
Galapagos NV is a Belgium-based biotechnology company focused on developing meaningful medicines for patients with serious diseases in areas of high unmet medical need. Leveraging a modality-agnostic approach and strong dealmaking capabilities, it targets oncology and immunology & inflammation assets with clear clinical proof-of-concept to create value for both patients and shareholders.
Average Trading Volume: 114,088
Technical Sentiment Signal: Hold
Current Market Cap: $2.16B
Find detailed analytics on GLPG stock on TipRanks’ Stock Analysis page.